Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors

Jiang, Tao; Wei, Bojun; Zhang, D X; Li, L; Yao, Xiaoai; Chen, Z W; Liu, X; Du, Xuemei

doi:10.1007/s00198-019-04959-y

Cited by 8 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, regulation of the EMT pathway was one of the top enriched canonical pathways in metastatic compared to non-metastatic PCs. The contribution of lncRNAs to the development of malignant and benign parathyroid tumors has been investigated indifferent studies and some of them might be useful markers in differentiating PCs from PAs (Jiang et al 2019, Morotti et al 2020.…”

Section: :2mentioning

confidence: 99%

Gene expression profile in metastatic and non-metastatic parathyroid carcinoma

Condello

Cetani

Denaro

et al. 2021

Endocrine-Related Cancer

View full text Add to dashboard Cite

Parathyroid carcinoma (PC) is one of the rarest and aggressive malignancies of the endocrine system. In some instances the histological diagnosis remains uncertain unless there is evidence of gross local invasion or secondary spread. The identification of molecular markers could improve the diagnostic accuracy of these lesions. The expression of 740 genes involved in the tumor progression processes was assessed in 8 parathyroid adenomas (PAs), 17 non-metastatic and 10 metastatic PCs using NanoString technology. Clustering analysis and Ingenuity Pathway Analysis (IPA) were interrogated to compare the gene expression profiles among the three analyzed groups and to evaluate the potential role of differentially expressed genes, respectively. The 103 differentially expressed genes between metastatic PCs and PAs are able to discriminate perfectly the two groups from a molecular point of view. The molecular signatures identified in non-metastatic PCs vs. PAs and in metastatic PCs vs. non-metastatic PCs comparisons, although with some exceptions, seem to be histotype-specific IPA reveals that hepatic fibrosis/hepatic stellate cell activation and GP6 signaling pathway are involved in malignant behavior of parathyroid tumors, whereas the activation of the HOTAIR regulatory pathway are involved in the metastatization process. Our investigation identified differentially expressed genes in non-metastatic PCs mainly encoding ECM proteins and in metastatic PCs driving endothelial-to-mesenchymal transition or encoding mediators of angiogenesis. The identified genes might be promising molecular markers potentially useful in the clinical practice for the early diagnosis and prognosis of PC.

show abstract

Section: :2mentioning

confidence: 99%

Gene expression profile in metastatic and non-metastatic parathyroid carcinoma

Condello

Cetani

Denaro

et al. 2021

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…A P < 0.05 was considered as statistically significant. Method for lncRNA score calculation was described previously [9].…”

Section: Discussionmentioning

confidence: 99%

“…Glyceraldeyde-3-phosphate dehydrogenase (GAPDH) was validated as housekeeping gene (F 5′-TGACTTCAACAGCGACAC CCA-3′ and R 5′-CACCCTGTTGCTGTAGCCAAA-3′) and served as internal control. Primers for lncRNAs (LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1) identified were significantly) involved in lncRNA score were as we previously described [9]. The qPCR experiments were conducted as follows: 95°C denaturation for 10 min; 40 cycles at 95°C for 10 s, 60°C for 60 s, and 95°C for 15 s. The relative expression level of PVT1 was analyzed using 2 -ΔΔCT method.…”

Section: Reverse-transcription Quantitative Polymerase Chain Reaction (Rt-qpcr)mentioning

confidence: 99%

“…Long non-coding RNAs (lncRNAs), greater than 200 nucleotides in length, are deregulated in endocrine system disorders, such as thyroid cancer [5][6][7] and adrenocortical cancer [8]. Our recent study demonstrated that four lncRNAs were involved in hyperparathyroidism [9]. LncRNA score was calculated by the expression levels of LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2: 1.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study

Zhang

Wei

et al. 2021

Journal of Otolaryngology - Head & Neck Surgery

View full text Add to dashboard Cite

Background Dysregulated lncRNA score and PVT1 expression may be involved in cancer. However, relationships of lncRNAs with hyperparathyroidism and parathyroid cancer (PC) diagnosis remain mysterious. Methods Using quantitative real-time polymerase chain reaction (RT-qPCR), expression profile of PVT1 was evaluated in 57 patients with primary hyperparathyroidism, including 11 with parathyroid cancer (PC) and 46 with parathyroid adenoma (PA). Results Higher levels of lncRNA score and PVT1 expression were associated with increased serum calcium level after water ingestion and PC risk (P < 0.05). Accordingly, lncRNA score and PVT1 expression were increased with varying degrees of hypercalcemia in PC. A higher level of lncRNA score (but not PVT1) was an independent risk factor of PC, with an AUC up to 0.872 (95% CI: 0.756–0.945, P < 0.001). Moreover, lncRNA score was more valuable (with AUC 0.974, sensitivity of 85.71% and specificity of 100%, respectively) than intact parathyroid hormone (iPTH) in predicting risk of PC among patients with hypercalcemia (especially based on greater AUC, P = 0.010). Conclusion Increased lncRNA score is correlated with an elevated level of serum calcium, which may serve as a potential biomarker for PC diagnosis, especially with hypercalcemia. Graphical abstract

show abstract

“…(21) Unfortunately, no differentially expressed lncRNA from our analysis was shared with previous literature on deregulation of lncRNAs in parathyroid tumors. (25,35) This could be related to the different platforms used to screen expression of lncRNAs in parathyroid tissues or to the elevated molecular heterogeneity of parathyroid tumors. Nevertheless, the two previous reports and ours could document that lncRNAs may serve as novel biomarkers for parathyroid tumor diagnosis.…”

Section: Discussionmentioning

confidence: 99%

The Oncosuppressors MEN1 and CDC73 Are Involved in lncRNA Deregulation in Human Parathyroid Tumors

Morotti

Forno

Verdelli

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

A role for long non‐coding RNAs (lncRNAs) in endocrine cancer pathogenesis is emerging. However, knowledge regarding their expression pattern, correlation with known genetic defects, and clinical implications in parathyroid tumors is still unclear. Here, we profiled 90 known lncRNAs in a first series of normal (PaN = 2), adenomatous (PAd = 12), and carcinomatous (PCa = 4) parathyroid glands and we confirmed deregulation of 11 lncRNAs using an independent cohort of patients (PaN = 4; PAd = 26; PCa = 9). Expression of lncRNAs was correlated with cytogenetic aberrations, status of genes multiple endocrine neoplasia 1 (MEN1) and cell division cycle 73 (CDC73), or clinical features. Globally, lncRNAs discriminate according to tissue histology. BC200 consistently identifies parathyroid cancers from adenomas and atypical adenomas. Loss‐of‐heterozygosity (LOH) at chromosomes 1, 11, 15, 21, and 22 significantly impacts expression of lncRNAs in PAds. Silencing of the key parathyroid gene MEN1 modulates the expression of six lncRNAs in primary PAds‐derived cultures. Analogous levels of lncRNAs are measured in PAds with the mutation in the MEN1 gene compared with PAds with wild‐type MEN1. Similarly, carcinomas with mutated CDC73 differ from PCas with wild‐type protein in terms of expression of lncRNAs. PCas harboring CDC73 mutations overexpress BC200 compared to wild‐type carcinomas. Overall, these findings shed light on deregulation of lncRNAs in human parathyroid tumors and propose that circuits between lncRNAs and the oncosuppressors MEN1 or CDC73 may have a role in parathyroid tumorigenesis as epigenetic modulators. © 2020 American Society for Bone and Mineral Research (ASBMR).

show abstract

Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors

Cited by 8 publications

References 31 publications

Gene expression profile in metastatic and non-metastatic parathyroid carcinoma

Gene expression profile in metastatic and non-metastatic parathyroid carcinoma

Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study

The Oncosuppressors MEN1 and CDC73 Are Involved in lncRNA Deregulation in Human Parathyroid Tumors

Contact Info

Product

Resources

About